tirzepatide shortage Trade group sues FDA over ending Mounjaro/Zepbound Tirzepatide is NO longer in
Description
While the currently approved GLP-1 therapies have transformed obesity management, they represent only the first wave of innovation
Blog Semaglutide flow trial result Promising Data from the First Dedicated Kidney Outcomes Trial with GLP-1 Receptor Agonist, Semaglutide, in Patients with Type 2 Diabetes and Chronic Kidney Disease On 11 September 2024, the latest results from the FLOW trial were presented at the European Association for the Study of Diabetes (EASD) conference in Madrid, Spain
This data guides PlexusDx in recommending the optimal compoundsemaglutide, tirzepatide, GLP-Squared, or microdose protocolspecifically matched to your hunger biology
Can you support clinical trial material production
They tested liraglutide, an older GLP-1 drug, on 31 patients with obesity and unresponsive migraines for 12 weeks
